← Map · Health Care Equipment · S&P 500 · $126.4B · Last Jul 30 AMC
SYK STRYKER
Yes — Mako is the needle
What they are doing
Diversified device company. We score the enabling thread, not the catalog. On the Q2 call, CEO Kevin Lobo tied US growth to Mako: Ortho +9.1%, knees +6.2%, hips +4.9%. Mako: 20 years, 2.5M+ procedures, 45 countries, commercial push on Mako RSP. Prophecy = patient-specific planning. 2.5M procedures is franchise proof, not AI proof. The rest of the call was cyber recovery, vascular backorder, bubucass. They did not narrate an AI stack. The 10-K adds Vocera-class virtual care and ops AI (hygiene).
Why the score
- Reach 3 not 4: Mako + planning + Medical/Vocera. Ops AI is not a third needle.
- Weight 4 not 5: Mako changes the joint sale. Still an implant company with a robot.
- Proof 4 not 5: hardware volume. No revision or attach KPI this quarter.
What would move it next quarter: Outcome or attach on Mako / RSP / Prophecy, or Medical AI in the P&L.
Open these first
Evidence
riousMember us-gaap:TrademarksMember 2024-01-01 2024-12-31 0000310764 syk:InariMedicalInc.MergerMember us-gaap:OtherIntangibleAssetsMember 2025-01-01 2025-12-31 0000310764 syk:RecallMattersMember 2025-12-31 0000310764 syk:SpineReportingUnitMember 2025-01-01 2025-12-31 0000310764 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember syk:SpinalImplantsM urgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care dis
cquisition of AVS for net cash consideration of $ 435 and up to $ 400 in future milestone payments that had a fair value of $ 271 at the acquisition date. AVS is developing a next-generation intravascular lithotripsy platform designed to treat complex peripheral arterial disease. AVS is part of our Peripheral Vascular business within MedSurg and Neurotechnology. A cqu ion (Instruments), endoscopic and communications systems (Endoscopy), patient handling, emergency medical equipment, intensive c
Lobo on Mako, knees/hips, RSP — not an AI-strategy call
Slides and replay